Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Thursday. They presently have a $25.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 131.37% from the company’s previous close.

The analysts wrote, “Aquinox reported 3Q17 financial results this week. Phase 3 LEADERSHIP 301 trial of rosiptor continues to enroll pts and company continues to guide for top-line results in 3Q18. We expect a positive outcome based on Phase 2 data and reiterate BUY.””

Several other brokerages also recently weighed in on AQXP. ValuEngine downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, BidaskClub downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $22.80.

Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.27 during trading hours on Thursday, reaching $10.81. 60,433 shares of the company traded hands, compared to its average volume of 68,510. Aquinox Pharmaceuticals has a 12-month low of $10.45 and a 12-month high of $19.97.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/09/aquinox-pharmaceuticals-aqxp-buy-rating-reiterated-at-needham-company-llc.html.

Hedge funds have recently added to or reduced their stakes in the business. Archon Partners LLC raised its position in shares of Aquinox Pharmaceuticals by 44.0% during the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after buying an additional 5,500 shares in the last quarter. Alps Advisors Inc. raised its position in shares of Aquinox Pharmaceuticals by 4.7% during the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after buying an additional 939 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Aquinox Pharmaceuticals by 16.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Aquinox Pharmaceuticals during the 2nd quarter worth about $874,000. Finally, Northern Trust Corp raised its position in shares of Aquinox Pharmaceuticals by 3.3% during the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after buying an additional 2,691 shares in the last quarter. Institutional investors own 95.15% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.